Human GALP (3-32) (Galanin-like peptide (3-32)) serves as a high-affinity agonist for galanin receptors GalR1 (IC50 = 33 nM) and GalR2 (IC50 = 15 nM), as evidenced by competitive binding studies. It demonstrates significant potency in modifying the extracellular acidification rate in SH-SY5Y cells expressing GalR2 (EC50 = 360 nM) [1].